Visual analysis of the use of sacubitril/valsartan based on CiteSpace
- VernacularTitle:基于CiteSpace的沙库巴曲缬沙坦应用可视化分析
- Author:
Xinrui CAO
1
,
2
;
Simin YAN
2
;
Ruobin ZHANG
3
;
Weihong GE
2
Author Information
1. Nanjing Drum Tower Hospital Clinical College，Nanjing University of Chinese Medicine，Nanjing 210029，China
2. Dept. of Pharmacy，Nanjing Drum Tower Hospital，the Affiliated Hospital of Nanjing University Medical School，Nanjing 210008，China
3. Dept. of Pharmacy，Nanjing Drum Tower Hospital，China Pharmaceutical University，Nanjing 210008，China
- Publication Type:Journal Article
- Keywords:
sacubitril/valsartan;
CiteSpace;
visual analysis;
hotspot
- From:
China Pharmacy
2023;34(16):1989-1994
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the research status and development trends of the use of sacubitril/valsartan. METHODS Related literature about the use of sacubitril/valsartan were retrieved from CNKI and the core database of Web of Science. CiteSpace 5.8.R3 software was used to analyze authors， countries/areas， institutions and keywords. RESULTS & CONCLUSIONS Totally 1 193 Chinese literature and 1 060 English literature were included. The number of literature increased， with numerous literature covering the United States （429）， the United Kingdom （185） and China （184）. ZHANG Jing （5） and Solomon S D （118） published the highest number of Chinese and English articles. The authors of Chinese literature had less cooperation while the authors of English literature were in close contact. Dept. of Cardiology in the First Affiliated Hospital of Zhengzhou University （9）， Dept. of Cardiology in the Affiliated Hospital of Xuzhou Medical University （9） and Novartis AG （134） had the highest quantity of publications of Chinese and English literature. The institutions of Chinese literature had a small number of overall publications and less cooperation while the institutions of English literature were closely connected. The clinical efficacy of sacubitril/valsartan for heart failure， hypertension and their complications were research hotspots in Chinese and English literature. Chinese scholars and research teams need to strengthen cooperation and communication in the future， as well as conduct research from the perspectives of sacubitril/valsartan in the treatment of heart failure， hypertension and related complication， the improvement of oxidative stress， and the evaluation of the efficacy of combination therapy with dapagliflozin.
